Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CDA | P32320 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25807895 | 0.91 | ADK (0.40) | MAPTCDAADKTAS1R3TAS1R1 | |
| SCHEMBL22577499 | 0.82 | MAPT (0.51) | MAPTCDA | |
| SCHEMBL25807900 | 0.79 | ADK (0.31) | ADK | |
| SCHEMBL25807892 | 0.79 | POLB (0.37) | — | |
| SCHEMBL25807876 | 0.73 | MAPT (0.31) | MAPTCDA | |
| SCHEMBL23619486 | 0.71 | — | — | |
| SCHEMBL25808051 | 0.70 | MAPT (0.38) | MAPTCDA | |
| SCHEMBL22577554 | 0.69 | TYMP (0.58) | — | |
| SCHEMBL26554377 | 0.69 | SLC28A1 (0.33) | MAPTCDAADK | |
| SCHEMBL26554402 | 0.69 | SLC28A1 (0.33) | MAPTCDAADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | MAPT 4841/4885CDA 134/4885ADK 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.